(+34) 955 292 290 info@uxafarma.com

Bibliografía: Memantina como adyuvante en el tratamiento del TOC

BIBLIOGRAFÍA

  1. Fineberg, N.A.; Hengartner, M.P.; Bergbaum, C.E.; Gale, T.M.; Gamma, A.; Ajdacic-Gross, V.; Rössler, W.; Angst, J. A prospec- tive population-based cohort study of the prevalence, incidence and impact of obsessive-compulsive symptomatology. Int. J. Psychiatry Clin. Pract., 2013, 17(3), 170-178. [http://dx.doi.org/10.3109/ 13651501.2012.755206] [PMID: 23205952]
  2. Kalra, S.K.; Swedo, S.E. Children with obsessive-compulsive disorder: are they just “little adults”? J. Clin. Invest., 2009, 119(4), 737-746. [http://dx.doi.org/10.1172/JCI37563] [PMID: 19339765]
  3. Saxena, S.; Rauch, S.L. Functional neuroimaging and the neuro- anatomy of obsessive-compulsive disorder. Psychiatr. Clin. North Am., 2000, 23(3), 563-586. [http://dx.doi.org/10.1016/S0193- 953X(05)70181-7] [PMID: 10986728]
  4. Burguière, E.; Monteiro, P.; Mallet, L.; Feng, G.; Graybiel, A.M. Striatal circuits, habits, and implications for obsessive-compulsive disorder. Curr. Opin. Neurobiol., 2015, 30, 59-65. [http://dx.doi. org/10.1016/j.conb.2014.08.008] [PMID: 25241072]
  5. Ting, J.T.; Feng, G. Neurobiology of obsessive-compulsive disor- der: insights into neural circuitry dysfunction through mouse genet- ics. Curr. Opin. Neurobiol., 2011, 21(6), 842-848. [http://dx.doi. org/10.1016/j.conb.2011.04.010] [PMID: 21605970]
  6. Shin, D.J.; Jung, W.H.; He, Y.; Wang, J.; Shim, G.; Byun, M.S.; Jang, J.H.; Kim, S.N.; Lee, T.Y.; Park, H.Y.; Kwon, J.S. The ef- fects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol. Psychiatry, 2014, 75(8), 606-614. [http://dx.doi.org/10.1016/j.biopsych.2013.09.002] [PMID: 24099506]
  7. Wu, K.; Hanna, G.L.; Rosenberg, D.R.; Arnold, P.D. The role of glutamate signaling in the pathogenesis and treatment of obsessive- compulsive disorder. Pharmacol. Biochem. Behav., 2012, 100(4), 726-735. [http://dx.doi.org/10.1016/j.pbb.2011.10.007] [PMID: 22024159]
  8. Javitt, D.C.; Schoepp, D.; Kalivas, P.W.; Volkow, N.D.; Zarate, C.; Merchant, K.; Bear, M.F.; Umbricht, D.; Hajos, M.; Potter, W.Z.; Lee, C.M. Translating glutamate: from pathophysiology to treat- ment. Sci. Transl. Med., 2011, 3, 102mr2. [http://dx.doi.org/10. 1126/scitranslmed.3002804]
  9. Siegel, S.; Sanacora, G. The roles of glutamate receptors across major neurological and psychiatric disorders. Pharmacol. Biochem. Behav., 2012, 100(4), 653-655. [http://dx.doi.org/10.1016/j.pbb. 2011.11.002] [PMID: 22108650]
  10. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disor- ders. Mol. Psychiatry, 2004, 9(11), 984-997, 979. [http://dx.doi.org/ 10.1038/sj.mp.4001551] [PMID: 15278097]
  11. Blackshaw, L.A.; Page, A.J.; Young, R.L. Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways. Front. Neurosci., 2011, 5, 40. [http://dx.doi.org/10.3389/fnins. 2011.00040] [PMID: 21472028]
  12. Wald, R.; Dodman, N.; Shuster, L. The combined effects of me- mantine and fluoxetine on an animal model of obsessive compul- sive disorder. Exp. Clin. Psychopharmacol., 2009, 17(3), 191-197. [http://dx.doi.org/10.1037/a0016402] [PMID: 19586234]
  13. Olatunji, B.O.; Davis, M.L.; Powers, M.B.; Smits, J.A. Cognitive- behavioral therapy for obsessive-compulsive disorder: a meta- analysis of treatment outcome and moderators. J. Psychiatr. Res., 2013, 47(1), 33-41. [http://dx.doi.org/10.1016/j.jpsychires.2012. 08.020] [PMID: 22999486]
  14. Foa, E.B.; Liebowitz, M.R.; Kozak, M.J.; Davies, S.; Campeas, R.; Franklin, M.E.; Huppert, J.D.; Kjernisted, K.; Rowan, V.; Schmidt, A.B.; Simpson, H.B.; Tu, X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combi- nation in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2005, 162(1), 151-161. [http://dx.doi.org/10.1176/ appi.ajp.162.1.151] [PMID: 15625214]
  15. Fineberg, N.A.; Reghunandanan, S.; Brown, A.; Pampaloni, I. Pharmacotherapy of obsessive-compulsive disorder: evidence- based treatment and beyond. Aust. N. Z. J. Psychiatry, 2013, 47(2), 121-141. [http://dx.doi.org/10.1177/0004867412461958] [PMID: 23125399]
  16. Ghaleiha A, Entezari N, Modabbernia A et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2O13; 47„ 175–180
  17. Stewart SE, Jenike EA, Hezel DM et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2O1O; 3O„ 34–3P
  18. Feusner JD, .erwin L, Saxena S et al. Differential eªcacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder„ an open-label trial. Psychopharmacol Bull 2OOP; 42„ 81–P3
  19. Goodman W., Price LH, Rasmussen SA et al. The Yale-brown obsessive compulsive scale. I. development, use, and reliability. Arch Gen Psychiatry 1P8P; 46„ 1OO6–1O11
  20. Modarresi, A., Sayyah, M., Razooghi, S., Eslami, K., Javadi, M., Kouti, L., … Blvd, G. (n.d.). Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder : A Randomized Controlled Trial.
  21. Grant, J. E., Chamberlain, S. R., Odlaug, B. L., Potenza, M. N., & Kim, S. W. (2010). Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: A pilot study. Psychopharmacology, 212(4), 603–612. https://doi.org/10.1007/s00213-010-1994-5
  22. Aboujaoude, E., Barry, J. J., & Gamel, N. (2009). Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Journal of Clinical Psychopharmacology, 29(1), 51–55. https://doi.org/10.1097/JCP.0b013e318192e9a4
  23. Pasquini, M., & Biondi, M. (2006). Memantine augmentation for refractory obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1173–1175. https://doi.org/10.1016/j.pnpbp.2006.04.013
  24. Haghighi, M., Jahangard, L., Mohammad-Beigi, H., Bajoghli, H., Hafezian, H., Rahimi, A., … Brand, S. (2013). In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology, 228(4), 633–640. https://doi.org/10.1007/s00213-013-3067-z
  25. Sahraian, A., Jahromi, L. R., Ghanizadeh, A., & Mowla, A. (2017). Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Psychopharmacology, 37(2), 246–249. https://doi.org/10.1097/JCP.0000000000000651
  26. Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., … Akhondzadeh, S. (2013). Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research, 47(2), 175–180. https://doi.org/10.1016/j.jpsychires.2012.09.015
  27. Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Industrial Psychiatry Journal. 2013;22(2):149-152. doi:10.4103/0972-6748.132930.